Cabozantinib selectively induces proteasomal degradation of p53 somatic mutant Y220C and impedes tumor growth
Journal of Biological Chemistry · 2025
DOI: 10.1016/j.jbc.2025.108167 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025. Verfasst von Fang Lin Lv und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatopancreatobiliary Surgery, Suzhou Ninth Hospital Affiliated to Soochow University, Suzhou, Jiangsu, China; Department of Pharmacol…. Hauptthemen laut MEDLINE: Pyridines, Tumor Suppressor Protein p53, Proteasome Endopeptidase Complex, Anilides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Inactivation of p53 by mutations commonly occurs in human cancer. The mutated p53 proteins may escape proteolytic degradation and exhibit high expression in tumors and acquire gain-of-function activity that promotes tumor progression and chemo-resistance. Therefore, selectively targeting of the gain-of-function p53 mutants may serve as a promising therapeutic strategy for cancer prevention and treatment. In this study, we identified cabozantinib, a multikinase inhibitor currently used in the clinical treatment of several types of cancer, as a selective inducer of proteasomal degradation of the p53-Y220C mutant. We demonstrate that cabozantinib disrupts the interaction between p53Y220C and USP7, a deubiquitylating enzyme, resulting in the dissociation of p53Y220C protein from its binding with USP7 and subsequent ubiquitination and degradation mediated by CHIP (the carboxyl terminal of Hsp70-interacting protein). We also show that cabozantinib displays preferential cytotoxicity to p53Y220C-harboring cancer cells both in vitro and in vivo. This study demonstrates a novel, p53-Y220C mutant-targeted anticancer action and mechanism for cabozantinib and provides the rationale for use of this drug in the treatment of cancers that carry the p53-Y220C mutation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatopancreatobiliary Surgery, Suzhou Ninth Hospital Affiliated to Soochow University, Suzhou, Jiangsu, China; Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, J…
- Department of Respiratory Medicine, First Affiliated Hospital, Soochow University, Suzhou, Jiangsu, China.
- Department of Gynecology and Obstetrics, First Affiliated Hospital, Soochow University, Suzhou, Jiangsu, China.
- Department of Cancer Biology and Toxicology, Markey Cancer Center, University of Kentucky, College of Medicine, Lexington, Kentucky, USA.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Lv, F. L., Zhang, L., Ji, C., Peng, L., Zhu, M., Yang, S., Dong, S., Zhou, M., Guo, F., Li, Z., Wang, F., Chen, Y., Zhou, J., Ren, X., Shen, G., Yang, J. M., Li, B., & Zhang, Y. (2025). Cabozantinib selectively induces proteasomal degradation of p53 somatic mutant Y220C and impedes tumor growth. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.108167
Vancouver
Lv FL, Zhang L, Ji C, Peng L, Zhu M, Yang S, et al. Cabozantinib selectively induces proteasomal degradation of p53 somatic mutant Y220C and impedes tumor growth. Journal of Biological Chemistry. 2025. doi:10.1016/j.jbc.2025.108167
BibTeX
@article{Lv2025,
author = {Lv, Fang Lin and Zhang, Lu and Ji, Cheng and Peng, Lei and Zhu, Mingxian and Yang, Shumin and Dong, Shunli and Zhou, Mingxuan and Guo, Fanfan and Li, Zhenyun and Wang, Fang and Chen, Youguo and Zhou, Jinhua and Ren, Xingcong and Shen, Genhai and Yang, Jin-Ming and Li, Bin and Zhang, Yi},
title = {Cabozantinib selectively induces proteasomal degradation of p53 somatic mutant Y220C and impedes tumor growth},
journal = {Journal of Biological Chemistry},
year = {2025},
doi = {10.1016/j.jbc.2025.108167}
}
EUVIMED